tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Calidi Biotherapeutics Secures FDA Fast Track Designation

Story Highlights
  • Calidi Biotherapeutics presented preclinical data and received FDA Fast Track Designation.
  • The company raised $4.6 million, strengthening its financial position despite a net loss.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Calidi Biotherapeutics Secures FDA Fast Track Designation

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Calidi Biotherapeutics ( (CLDI) ) has issued an update.

In the second quarter of 2025, Calidi Biotherapeutics reported significant progress in its operations, including the presentation of preclinical data on its lead compound CLD-401 and receiving FDA Fast Track Designation for CLD-201. The company also raised $4.6 million through a warrant inducement offering, strengthening its financial position amid a challenging biotech financing environment. Despite a net loss of $5.7 million, Calidi continues to advance its innovative therapies targeting high unmet medical needs in cancer treatment.

The most recent analyst rating on (CLDI) stock is a Buy with a $2.50 price target. To see the full list of analyst forecasts on Calidi Biotherapeutics stock, see the CLDI Stock Forecast page.

Spark’s Take on CLDI Stock

According to Spark, TipRanks’ AI Analyst, CLDI is a Underperform.

Calidi Biotherapeutics’ overall stock score reflects significant financial and technical challenges, typical of a developing biotech company. While corporate events bring positive leadership changes and strategic advancements, the company’s lack of revenue, high leverage, and bearish technical indicators weigh heavily on its score.

To see Spark’s full report on CLDI stock, click here.

More about Calidi Biotherapeutics

Calidi Biotherapeutics is a clinical-stage immuno-oncology company based in San Diego, California, focused on developing targeted therapies that deliver genetic medicines to distal disease sites. The company utilizes its proprietary Redtail platform, which features an engineered enveloped oncolytic virus designed for systemic delivery and targeting of metastatic sites, aiming to shield the virus from immune clearance and effectively reach tumor sites.

Average Trading Volume: 1,457,830

Technical Sentiment Signal: Sell

Current Market Cap: $17.78M

For a thorough assessment of CLDI stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1